Determinants of appropriate lipid management in patients with ischaemic heart disease. Cracovian program for secondary prevention of ischaemic heart disease

International Journal of Cardiology

Volumn 91, Issue 1, 2003, Pages 15-23

  Kawecka Jaszcz, Kalina ^a   Jankowski, Piotr ^a   Paja̧k, Andrzej ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Cholesterol; Compliance; Guidelines; Ischaemic heart disease; Lipid lowering drugs

Indexed keywords

ANTILIPEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ANAMNESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMMUNITY HOSPITAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DISEASE ASSOCIATION; EDUCATION; EVALUATION; FEMALE; FOLLOW UP; HEALTH CARE MANAGEMENT; HEALTH PROGRAM; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITAL DEPARTMENT; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTERVIEW; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD; OBESITY; OUTCOMES RESEARCH; OUTPATIENT DEPARTMENT; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROBABILITY; SECONDARY PREVENTION; TIME; UNIVERSITY HOSPITAL; UNSTABLE ANGINA PECTORIS;

EID: 0041327695     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00580-6     Document Type: Article

References (19)

1. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
2. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level. New Engl J Med. 335:1996;1001-1009.
3. Pyörälä K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 15:1994;1300-1331.
4. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation. 89:1994;1329-1445.
5. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J. 18:1997;1569-1582.
6. Sueta C.A., Chowdhury M., Boccuzzi S.J., Smith S.C. Jr., Alexander C.M., Londhe A., et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart disease secondary to coronary artery disease. Am J Cardiol. 83:1999;1303-1307.
7. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Euro Heart Survey Programme. Eur Heart J. 22:2001;554-572.
8. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. J. Am. Med. Assoc. 279:1998;1643-1650.
9. Rich S.E., Shah J., Rich D.S., Shah R., Rich M.W. Effects of age, sex, race, diagnosis-related group and hospital setting on lipid management in patients with coronary artery disease. Am J Cardiol. 86:2000;328-330.
10. Vanuzzo D., Pilotto L., Ambrosio G.B., Pyorala K., Lehto S., De Bacquer D., et al. Potential for cholesterol lowering in secondary prevention of coronary heart disease in Europe: findings from EUROASPIRE study. Atherosclerosis. 153:2000;505-517.
11. Lee T.H., Cleeman J.I., Grundy S.M., Gillett C., Pasternak R.C., Seidman J., et al. Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease. J. Am. Med. Assoc. 283:2000;94-98.
12. 27th Bethesda Conference. Matching the Intensity of Risk Factor Management with the Hazard for Coronary Disease Events. J Am Coll Cardiol 1996;27:957-1047.
13. Stamos T.D., Shaltoni H., Girard S.A., Parrillo J.E., Calvin J.E. Effectiveness of chart prompts to improve physician compliance with the national cholesterol education program guidelines. Am J Cardiol. 88:2001;1420-1423.
14. Muhlestein J.B., Horne B.D., Bair T.L., Li Q., Madsen T.E., Pearson R.R., et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol. 87:2001;257-261.
15. Stagmo M., Westin L., Carlsson R., Israelsson B. Long-term effects on cholesterol levels and the utilization of lipid-lowering drugs of a hospital-based programme for secondary prevention of coronary artery disease. J Cardiovasc Risk. 8:2001;243-248.
16. Fonarow G.C., Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. Am J Cardiol. 85:2000;10A-17A.
17. Smith D.A., Harnick D.A., Kilaru R. Comparison of physician-managed lipid-lowering care in patients with coronary heart disease in two time periods (1994 and 1999). Am J Cardiol. 88:2001;1417-1419.
18. Harnick D.J., Cohen J.L., Schechter C.B., Fuster V., Smith D.A. Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease. Am J Cardiol. 81:1998;1416-1420.
19. Massing M.W., Sueta C.A., Chowdhury M., Biggs D.P., Simpson R.J. Jr. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol. 87:2001;646-649.